Site icon MARKET BARRISTER

Gensol Engineering -Why Investor Cry-SEBI Investigation-Fund Diverted -falling from Rs.1376 & dropped 90 percent

Gensol Engineering

Gensol Engineering

Gensol Engineering -Why Investor Cry-SEBI Investigation-Fund Diverted -falling from Rs.1376 & dropped 90 percent

Gensol Engineering’s stock has been experiencing a sharp decline over the past 10 weeks, continuing a downtrend that began in February 2024. Despite the company gradually reporting good financials, the stock performance has worsened significantly, with prices taking a steep nosedive.

Stock Trades both on NSE, BSE 

Read ….

Natco Pharma Falling from  ₹ 1639 Rs to 55 % Low 

Subscribe for latest updates for stock news Market Barrister 

PEER Group Debt to Equity Ratio and Mkt Cap 

Gensol Engineering Financial

Gensol Engineering has delivered strong results in recent quarters, showing consistent sales growth and steadily improving profitability.

Share Holding Pattern of Dec’2024

What Led Stock Crash   ?

SEBI Action Against Gensol Engineering Promoters

SEBI has taken strict action against Gensol Engineering’s promoters, Anmol Singh Jaggi and Puneet Singh Jaggi. Both have been removed from any director roles in the company and are banned from accessing the stock market. SEBI also told the company to pause its recently announced stock split.

From 2021 to 2024, Gensol took loans worth ₹978 crore from IREDA and PFC. Out of this, ₹664 crore was meant to buy 6,400 electric vehicles (EVs) for leasing to BluSmart. Gensol was also supposed to add 20% of its own money, making the total spend around ₹830 crore.

But in a February 2025 update, Gensol said it had only bought 4,704 EVs so far. Their supplier, Go-Auto, confirmed the total cost of those EVs was ₹568 crore. SEBI pointed out that there’s a missing amount of ₹262 crore that hasn’t been explained, even after more than a year since the last loan was received.

Bank records also show possible fund diversion linked to Puneet Singh Jaggi.

Disclaimer

 Alert

The information provided on this website is for educational and informational purposes only and should not be considered as financial, investment, or trading advice. All content, including stock analyses, market data, and opinions, is based on publicly available information believed to be accurate at the time of publication

https://marketbarrister.com/natco-pharma-declined-from-inr-1639-to-inr-726-what-is-the-factor/

 

SKIN CARE

Exit mobile version